Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Puma Biotechnology, Inc. (NASDAQ:PBYI) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.15 and traded as high as $3.61. Puma Biotechnology shares last traded at $3.55, with a volume of 127,438 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 22nd.

Puma Biotechnology Stock Down 0.3%

The company has a market capitalization of $176.19 million, a P/E ratio of 4.61 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43. The company has a 50 day moving average of $3.33 and a 200-day moving average of $3.15.

Insider Activity at Puma Biotechnology

In related news, Director Troy Edward Wilson sold 10,800 shares of the business’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $36,720.00. Following the transaction, the director owned 43,550 shares in the company, valued at $148,070. The trade was a 19.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allison Dorval sold 11,610 shares of the firm’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $39,474.00. Following the completion of the sale, the director owned 75,390 shares of the company’s stock, valued at $256,326. This trade represents a 13.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 91,660 shares of company stock valued at $311,563 over the last 90 days. Company insiders own 23.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PBYI. Wells Fargo & Company MN lifted its stake in shares of Puma Biotechnology by 36.5% in the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 6,126 shares during the period. Mackenzie Financial Corp purchased a new position in Puma Biotechnology during the fourth quarter valued at $240,000. Bank of New York Mellon Corp lifted its position in Puma Biotechnology by 19.5% during the fourth quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 54,150 shares during the period. American Century Companies Inc. boosted its holdings in shares of Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company’s stock valued at $2,893,000 after buying an additional 73,833 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Puma Biotechnology by 182.3% in the 4th quarter. JPMorgan Chase & Co. now owns 136,897 shares of the biopharmaceutical company’s stock worth $418,000 after buying an additional 88,404 shares during the period. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.